The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.
Johanna C. Bendell
No relevant relationships to disclose
James D. Peyton
No relevant relationships to disclose
Scott Ryan Sommers
No relevant relationships to disclose
Henry Q. Xiong
No relevant relationships to disclose
Edward J. Crane
No relevant relationships to disclose
William N. Harwin
No relevant relationships to disclose
Mark Kozloff
No relevant relationships to disclose
Dianna Shipley
No relevant relationships to disclose
Dana Shelton Thompson
No relevant relationships to disclose
Mark Womack
No relevant relationships to disclose
Suzanne Fields Jones
No relevant relationships to disclose
Andrew H. Ko
Consultant or Advisory Role - Oncogenex (U)
Other Remuneration - Oncogenex